- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04003597
'Low-salt' Bread as a Means of Reducing Dietary Salt and Lowering Blood Pressure (Saltbreads)
'Low-salt' Bread as Part of a Pragmatic Reduced-salt Diet for Lowering Blood Pressure in Adults With Elevated Blood Pressure
In the context of public health, reformulation of bread in terms of salt content remains an important measure to help achieve a reduction in salt intake in the population. Therefore, the aim of this study was to examine, using a 5-week cross-over design, food-based intervention trial, the potential for inclusion of 'low-salt' bread as part of a pragmatic reduced-salt diet on blood pressure (BP) in adults with slightly to moderately elevated BP.
The study consisted of a randomized crossover trial of the effect of reduced-salt intake or usual-salt intake for 5 weeks on BP (as the primary outcome) in adults with slightly to moderately elevated BP (seated office systolic BP >120 and <160 mmHg or a diastolic BP >80 and <95 mmHg; identified by a pre-screening phase).
Subjects were randomly assigned to the reduced-salt diet or their usual-salt diet (control) for 5 weeks, followed by crossover to the alternative dietary regimen for a further 5 weeks. Subjects randomized to start on the reduced-salt diet were asked to restrict their consumption of dietary salt using a combination of pragmatic dietary advice as well as the replacement of bread and a limited number of other foods with equivalent foods which had lower salt content; these were provided to the participants. At the beginning of the salt restriction period, a research nutritionist provided the subjects with a list of the common salt-containing food and were asked to limit the consumption of such, as feasible. The subjects received in-house prepared 'low-salt (<0.3 g/100 g)' brown or white sliced pan bread as well as no-salt margarine/butter, and were given luncheon meats with no added salt, if desired (optional); these were supplied regularly by the research staff. Subjects commencing the trial on the control diet were allowed to follow their usual diet but were asked to consume an in-house produced brown or white sliced pan bread equivalent in composition to the low-salt version but with its more typical salt content (1.2 g/100 g).
Participants met the research staff weekly to receive breads and no-salt margarine/butter as well as luncheon meats (where applicable), and at these meetings the staff promoted compliance with the intervention and encouraged completion of the study protocol.
BP and other assessments were made at baseline and at the end of week 5 and week 10.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Brief background and context for the study:
The World Health Organization's Global Action Plan for the Prevention and Control of Non-Communicable Disease includes a voluntary global target of a 30% relative reduction in mean population intake of salt/sodium by 2025. Bread and cured/processed meats collectively contribute anything from about a third upwards of total salt intake of adults in many Western countries. Reformulation of bread in terms of salt content remains an important measure to help achieve a reduction in salt intake in the population. Therefore, the aim of this study was to examine, using a 5-week cross-over design, food-based intervention trial, the potential for inclusion of 'low-salt' bread as part of a pragmatic reduced-salt diet on blood pressure (BP) in adults with slightly to moderately elevated BP.
Design:
The study consisted of a randomized crossover trial of the effect of reduced-salt intake or usual-salt intake for 5 weeks on BP (primary outcome) and biochemical markers of calcium and bone metabolism as well as plasma lipids (secondary outcomes) in adults with slightly to moderately elevated BP.
Potential volunteers were screened for BP over 3 weeks preceding the intervention phase of the trial during which seated office systolic and diastolic BP were measured weekly and those with systolic BP >120 and <160 mmHg or a diastolic BP >80 and <95 mmHg were considered eligible.
The dietary intervention phase of the trial was designed in two successive dietary periods, each of 5 weeks. Subjects were randomly assigned to the reduced-salt diet or their usual-salt diet (control) for 5 weeks, followed by crossover to the alternative dietary regimen for a further 5 weeks. At baseline (week 0), the subjects visited the Human Nutrition Studies Unit within University College Cork in a fasting state and had their BP measured. Prior to the baseline visit, subjects received instructions on how to collect a 24-h urine sample and were provided with a suitable container for collection. On the day of the baseline visit, subjects brought the 24-h urine sample collected from the previous day and deposited it in a cold room area dedicated for such collections. A blood sample was taken from each subject between 08.30 am and 10.30 am by a trained phlebotomist and anthropometric measures including height and weight, were taken. A health and lifestyle questionnaire, which assessed physical activity, general health, smoking status and alcohol consumption was completed by each subject. Subjects randomized to start on the reduced-salt diet were asked to restrict their consumption of dietary salt using a combination of pragmatic dietary advice as well as the replacement of bread and a limited number of other foods with equivalent foods which had lower salt content; these were provided to the participants. At the beginning of the salt restriction period, a research nutritionist provided the subjects with a list of the common salt-containing food and were asked to limit the consumption of such, as feasible. The subjects received in-house prepared 'low-salt (<0.3 g/100 g)' brown or white sliced pan bread as well as no-salt margarine/butter, and were given luncheon meats with no added salt, if desired (optional). Subjects commencing the trial on the control diet were allowed to follow their usual diet but were asked to consume an in-house produced brown or white sliced pan bread equivalent in composition to the low-salt version but with its more typical salt content (1.2 g/100 g).
During the intervention phase, each participant made 2 further visits to the study unit, one each on the last day of dietary period 1 (week 5) and dietary period 2 (week 10). At these visits, BP measurements were taken as well as other anthropometric measures, including height and weight. An overnight fasting blood sample was also taken from each participant between 08.30 am and 10.30 am by a trained phlebotomist, and on each of the visits, the subjects provided a 24-hour urine sample collected the previous day. Following blood sampling the participants received their breakfast.
Participants met the research staff weekly to receive breads and no-salt margarine/butter as well as luncheon meats (where applicable), and at these meetings the staff promoted compliance with the intervention and encouraged completion of the study protocol.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Cork, Ireland
- School of Food and Nutritional Sciences, University College Cork
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- consenting adult Caucasian men and women, aged ≤65 y;
- a seated office systolic BP >120 and <160 mmHg and/or a diastolic BP >80 and <95 mmHg (based on the mean BP across 3 screening visits as part of a pre-intervention phase of the trial)
- willing to consume study breads
Exclusion Criteria:
- taking anti-hypertensive medication;
- taking any medications known to interfere with blood pressure or calcium or bone metabolism;
- Severe medical illness;
- celiac disease;
- hypercalcemia;
- known intestinal malabsorption syndrome,
- excessive alcohol use (>14 drinks/week);
- pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Usual-salt diet
Usual-salt diet followed for 5 weeks
|
Subjects followed their usual-salt diet but were asked to consume an equivalent in-house produced brown or white sliced pan bread equivalent in composition to the low-salt version but with its more typical salt content (1.2 g/100 g).
|
Active Comparator: Reduced-salt diet
Reduced-salt diet followed for 5 weeks
|
Subjects randomized to start on the reduced-salt diet were asked to restrict their consumption of dietary salt using a combination of pragmatic dietary advice as well as the replacement of bread and a limited number of other foods with equivalent foods which had lower salt content; these were provided to the participants.
At the beginning of the salt restriction period, a research nutritionist provided the subjects with a list of the common salt-containing food (salted and naturally salty) and were asked to limit the consumption of such, as feasible.
The subjects received in-house prepared 'low-salt (<0.3 g/100 g)' brown or white sliced pan bread as well as no-salt margarine/butter, and were given luncheon meats with no added salt if desired (optional).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Systolic blood pressure at end of intervention periods
Time Frame: After 5 weeks of intervention
|
Measured as seated office systolic blood pressure at end of usual salt dietary period and at end of reduced-salt dietary period
|
After 5 weeks of intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diastolic blood pressure
Time Frame: After 5 weeks of intervention
|
Measured as seated office diastolic blood pressure at end of usual salt dietary period and at end of reduced-salt dietary period
|
After 5 weeks of intervention
|
Urinary Calcium
Time Frame: After 5 weeks of intervention
|
Assessed in 24-hour urine collected at end of usual salt dietary period and at end of reduced-salt dietary period
|
After 5 weeks of intervention
|
Urinary N-telopeptides of Type I collagen
Time Frame: After 5 weeks of intervention
|
Biomarker of bone resorption; Assessed in 24-hour urine collected at end of usual salt dietary period and at end of reduced-salt dietary period
|
After 5 weeks of intervention
|
Serum Parathyroid Hormone
Time Frame: After 5 weeks of intervention
|
Index of calcium metabolism; Assessed in 24-hour urine collected at end of usual salt dietary period and at end of reduced-salt dietary period
|
After 5 weeks of intervention
|
Serum C-telopeptide of Type I collagen
Time Frame: After 5 weeks of intervention
|
Biomarker of bone resorption; Assessed in 24-hour urine collected at end of usual salt dietary period and at end of reduced-salt dietary period
|
After 5 weeks of intervention
|
Serum Osteocalcin
Time Frame: After 5 weeks of intervention
|
Biomarker of bone formation; Assessed in fasting serum collected at end of usual salt dietary period and at end of reduced-salt dietary period
|
After 5 weeks of intervention
|
Serum Bone-specific alkaline phosphatase
Time Frame: After 5 weeks of intervention
|
Biomarker of bone formation; Assessed in fasting serum collected at end of usual salt dietary period and at end of reduced-salt dietary period
|
After 5 weeks of intervention
|
Plasma triglycerides
Time Frame: After 5 weeks of intervention
|
Index of circulating lipids and CHD risk; Assessed in fasting plasma collected at end of usual salt dietary period and at end of reduced-salt dietary period
|
After 5 weeks of intervention
|
Serum total-cholesterol
Time Frame: After 5 weeks of intervention
|
Index of circulating lipids and CHD risk; Assessed in fasting plasma collected at end of usual salt dietary period and at end of reduced-salt dietary period
|
After 5 weeks of intervention
|
Plasma LDL-cholesterol,
Time Frame: After 5 weeks of intervention
|
Index of circulating lipids and CHD risk; Assessed in fasting plasma collected at end of usual salt dietary period and at end of reduced-salt dietary period
|
After 5 weeks of intervention
|
Plasma HDL-cholesterol
Time Frame: After 5 weeks of intervention
|
Index of circulating lipids and CHD risk; Assessed in fasting plasma collected at end of usual salt dietary period and at end of reduced-salt dietary period
|
After 5 weeks of intervention
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kevin D Cashman, PhD, University College Cork
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 06/rd/c/455
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Elevated Blood Pressure
-
Mati Therapeutics Inc.CompletedElevated Intraocular Pressure (IOP)United States
-
University Health Network, TorontoCompletedElevated Intracranial Pressure (ICP)Canada
-
Lashmi VenkatraghavanUniversity Health Network, TorontoCompletedElevated Intracranial Pressure (ICP)Canada
-
University Hospital, MontpellierCompletedElevated Left Atrial PressureFrance
-
MTI UniversityCompletedReducing the Elevated Blood Pressure for Diabetic Hypertensive PatientsEgypt
-
Lv YingjuanCompletedIntraocular PressureChina
-
China National Center for Cardiovascular DiseasesRecruiting
-
Beth Israel Deaconess Medical CenterAmerican Heart AssociationRecruitingHypertension | Elevated Blood PressureUnited States
-
University of California, San FranciscoTerminated
-
Calroy Health SciencesCompletedHypertension | Elevated Blood PressureUnited States
Clinical Trials on Usual-salt diet
-
University of MichiganRenal Research InstituteCompletedKidney DiseaseUnited States
-
University of Southern DenmarkOdense University Hospital; Beckett Foundation; Danish Diabetes AcademyCompleted
-
Brigham and Women's HospitalTerminatedAutoimmunity | Sodium Chloride | Salt Intake | Th17 Helper Immune CellsUnited States
-
Vanderbilt UniversityCompleted
-
Vanderbilt University Medical CenterCompletedObesity | Cardiovascular Risk Factor | Salt; ExcessUnited States
-
Aga Khan UniversityWellcome TrustUnknown
-
Hospital Clínico Universitario de ValladolidUnknown
-
Yale UniversityCompletedAutoimmune Hepatitis
-
University Hospital, GenevaCompleted
-
Josip Juraj Strossmayer University of OsijekRecruitingPsoriasis VulgarisCroatia